Sanofi US
Cambridge
Massachusetts
United States
229 articles about Sanofi US
-
Takeda hoped that its experimental therapy could become the first FDA-approved treatment for EoE. However, the FDA wants the company to initiate another clinical study with TAK-721.
-
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
-
Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease
11/30/2021
Sciwind Biosciences Co., Ltd. announced that it has signed a global, exclusive license agreement with Sanofi to develop and commercialize Sanofi's long-lasting glucose-dependent insulinotropic polypeptide receptor agonists, with the lead candidate currently under preclinical development.
-
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here's the first vaccine for RSV to shape the future.
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi
11/3/2021
Koneksa today announced that Sanofi, one of the world's top biopharmaceutical companies, has extended the two companies' collaboration in central nervous system (CNS) clinical trials.
-
Researchers found improvements in the study's co-primary endpoints in patient-reported measures of esophageal inflammation and difficulty swallowing.
-
Skin health logged major wins this week after two companies announced positive clinical trial results.
-
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
-
Recently launched biotech company Immunai is pairing artificial intelligence and machine learning in an attempt to tailor treatments and improve patient outcomes.
-
Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.
-
Two former executives of JHL Biotech were indicted on charges of orchestrating the theft of trade secrets, wire fraud exceeding $101 million, and money laundering.
-
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
-
Is an mRNA Flu Vaccine on the Horizon?
6/23/2021
The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus. -
This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.
-
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
-
Two of the company’s largest shareholders call for the ouster of a company director at Regeneron as top executives are under fire for their enormous compensation packages.
-
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
-
Sanofi said that the phase II/III trial studying venglustat in autosomal dominant polycystic kidney disease was scrapped because it “did not meet futility criteria.”
-
A two-stage Phase III clinical trial by Sanofi and GSK, is studying a COVID-19 vaccine candidate targeting the original SARS-CoV-2 strain as well as the South African B.1.351 variant.